The Latest Breaking News from ChemoCentryx

Upgrades

 

ChemoCentryx Inc (NASDAQ:CCXI) announced the presentation of preclinical data and initial pharmacokinetic (PK) and pharmacodynamic (PD) data from the ongoing Phase 1 study of CCX559 at the American Association for Cancer Research (AACR) Annual Meeting 2022. Preclinical characterization demonstrated that CCX559 is a potent inhibitor of PD-L1 that blocks binding to PD-1 and…

ChemoCentryx (NASDAQ:CCXI) brought in sales totaling $2.31 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 81.68%, resulting in a loss of $40.53 million.

Stifel has reiterated a Buy rating and $85 price target on ChemoCentryx Inc (NASDAQ:CCXI) following the Q4 results. Analyst Dae Gon Ha says he is "perplexed" by the pronounced weakness on what he views as a positive-launch quarter.  Ha tells investors in a research note that 127 patient start forms and 71% conversion rate strike…

ChemoCentryx Inc (NASDAQ: CCXI) shares are trading lower by 12.8% at $25.70 Wednesday morning after the company reported worse-than-expected fourth-quarter EPS and sales results.

ChemoCentryx (NASDAQ:CCXI) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

ChemoCentryx (NASDAQ:CCXI) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors need to know before the announcement. Analysts estimate that ChemoCentryx will report an earnings per share (EPS) of $-0.50.

Analysts and brokerage firms often use ratings when they issue stock recommendations to stock traders. Analysts arrive at stock ratings by researching public financial statements, communicating with executives and customers and following industry trends.